Lithium Carbonate 600 MG Oral Capsule

Brand Name: Lithium Carbonate
  • Substance Name(s):


Lithium may cause fetal harm when administered to a pregnant woman.

There have been reports of lithium having adverse effects on nidations in rats, embryo viability in mice, and metabolism in-vitro of rat testis and human spermatozoa have been attributed to lithium, as have teratogenicity in submammalian species and cleft palates in mice.

Studies in rats, rabbits and monkeys have shown no evidence of lithium-induced teratology.

Data from lithium birth registries suggest an increase in cardiac and other anomalies, especially Ebstein’s anomaly.

If the patient becomes pregnant while taking lithium, she should be apprised of the potential risk to the fetus.

If possible, lithium should be withdrawn for at least the first trimester unless it is determined that this would seriously endanger the mother.

Chronic lithium therapy may be associated with diminution of renal concentrating ability, occasionally presenting as nephrogenic diabetes insipidus, with polyuria and polydipsia.

Such patients should be carefully managed to avoid dehydration with resulting lithium retention and toxicity.

This condition is usually reversible when lithium is discontinued.

Morphologic changes with glomerular and interstitial fibrosis and nephron-atrophy have been reported in patients on chronic lithium therapy.

Morphologic changes have also been seen in bipolar patients never exposed to lithium.

The relationship between renal functional and morphologic changes and their association with lithium therapy has not been established.

When kidney function is assessed, for baseline data prior to starting lithium therapy or thereafter, routine urinalysis and other tests may be used to evaluate tubular function (e.g., urine specific gravity or osmolality following a period of water deprivation, or 24-hour urine volume) and glomerular function (e.g., serum creatinine or creatinine clearance).

During lithium therapy, progressive or sudden changes in renal function, even within the normal range, indicate the need for reevaluation of treatment.

Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels (see DOSAGE AND ADMINISTRATION ).


Drug interactions Combined Use Of Haloperidol and Lithium: An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leucocytosis, elevated serum enzymes, BUN and FBS) followed by irreversible brain damage has occurred in a few patients treated with lithium plus haloperidol.

A causal relationship between these events and the concomitant administration of lithium and haloperidol has not been established; however, patients receiving such combined therapy should be monitored closely for early evidence of neurological toxicity and treatment discontinued promptly if such signs appear.

The possibility of similar adverse interactions with other antipsychotic medication exists.

Lithium may prolong the effects of neuromuscular blocking agents.

Therefore, neuromuscular blocking agents should be given with caution to patients receiving lithium.

Caution should be used when lithium and diuretics or angiotensin converting enzyme (ACE) inhibitors are used concomitantly because sodium loss may reduce the renal clearance of lithium and increase serum lithium levels with risk of lithium toxicity.

When such combinations are used, the lithium dosage may need to be decreased, and more frequent monitoring of lithium plasma levels is recommended.

Non-Steroidal Anti-Inflammatory Drugs (NSAIDS): Lithium levels should be closely monitored when patients initiate or discontinue NSAID use.

In some cases, lithium toxicity has resulted from interactions between an NSAID and lithium.

Indomethacin and piroxicam have been reported to increase significantly steady-state plasma lithium concentrations.

There is also evidence that other nonsteroidal anti-inflammatory agents, including the selective cyclooxygenase-2 (COX-2) inhibitors, have the same effect.

In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with celecoxib 200 mg BID as compared to subjects receiving lithium alone.


The toxic levels for lithium are close to the therapeutic levels.

It is therefore important that patients and their families be cautioned to watch for early symptoms and to discontinue the drug and inform the physician should they occur.

Toxic symptoms are listed in detail under ADVERSE REACTIONS .

Treatment No specific antidote for lithium poisoning is known.

Early symptoms of lithium toxicity can usually be treated by reduction of cessation of dosage of the drug and resumption of the treatment at a lower dose after 24 to 48 hours.

In severe cases of lithium poisoning, the first and foremost goal of treatment consists of elimination of this ion from the patient.

Treatment is essentially the same as that used in barbiturate poisoning: 1) gastric lavage, 2) correction of fluid and electrolyte imbalance and 3) regulation of kidney functioning.

Urea, mannitol, and aminophylline all produce significant increases in lithium excretion.

Hemodialysis is an effective and rapid means of removing the ion from the severely toxic patient.

Infection prophylaxis, regular chest X-rays, and preservation of adequate respiration are essential.


Each capsule for oral administration contains 150 mg, 300 mg or 600 mg of Lithium Carbonate USP.

Inactive Ingredients The capsules contain talc.

The hard gelatin shell consists of gelatin, titanium dioxide, sodium lauryl sulphate and FD & C Red 40.

The printing ink contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, strong ammonia solution, black iron oxide E172 dye, potassium hydroxide.

Lithium is an element of the alkali-metal group with atomic number 3, atomic weight 6.94, and an emission line at 671 nm on the flame photometer.

The empirical formula for Lithium Citrate is C6H5Li3O7; molecular weight 209.92.

Lithium acts as an antimanic.

Lithium Carbonate is a white, light, alkaline powder with molecular formula Li2CO3 and molecular weight 73.89.


Lithium Carbonate Capsules USP 150 mg White/White hard gelatin capsules (size 4) Lithium Carbonate 150 mg Capsules are White/White size ‘4’ hard gelatin capsules, imprinted with ‘97’ on body and ‘H’ on cap, containing white to off-white powder.

They are supplied in Bottles of 30 Capsules (NDC 31722-544-30) Bottles of 100 Capsules (NDC 31722-544-01) Bottles of 500 Capsules (NDC 31722-544-05) Bottles of 1000 Capsules (NDC 31722-544-10) 300 mg Pink/Pink hard gelatin capsules (size 1) Lithium Carbonate 300 mg Capsules are Pink/Pink size ‘1’ hard gelatin capsules, imprinted with ‘98’ on body and ‘H’ on cap, containing white to off-white powder.

They are supplied in Bottles of 30 Capsules (NDC 31722-545-30) Bottles of 100 Capsules (NDC 31722-545-01) Bottles of 500 Capsules (NDC 31722-545-05) Bottles of 1000 Capsules (NDC 31722-545-10) Bottles of 5000 Capsules(NDC 31722-545-50) Blister Pack of 3×10’s (NDC 31722-545-03) 600 mg Pink/White hard gelatin capsules (size ‘0E’) Lithium Carbonate 600 mg Capsules are Pink/White size ‘0E’ hard gelatin capsules, imprinted with ‘141’ on body and ‘H’ on cap, containing white to off-white powder.

They are supplied in Bottles of 30 Capsules (NDC 31722-546-30) Bottles of 100 Capsules (NDC 31722-546-01) Bottles of 500 Capsules (NDC 31722-546-05) Bottles of 1000 Capsules (NDC 31722-546-10) Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

Protect from moisture.

Dispense in tight container as defined in the USP/NF.

Manufactured for: Camber Pharmaceuticals, Inc.

Piscataway, NJ 08854 By: Hetero Drugs Limited Jeedimetla, Hyderabad – 500 055, India.



Lithium Carbonate Capsule USP is indicated in the treatment of manic episodes of Bipolar Disorder.

Bipolar Disorder, Manic (DSM-III) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology.

Lithium Carbonate Capsule USP is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder.

Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur.

Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility.

When given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks.


Pregnancy Teratogenic Effects: Pregnancy Category D: See WARNINGS section.


Nursing Mothers Lithium is excreted in human milk.

Nursing should not be undertaken during lithium therapy except in rare and unusual circumstances where, in the view of the physician, the potential benefits to the mother outweigh possible hazards to the child.


WARNING Lithium toxicity is closely related to serum lithium levels, and can occur at doses close to therapeutic levels.

Facilities for prompt and accurate serum lithium determinations should be available before initiating therapy (see DOSAGE AND ADMINISTRATION ).


Information for the patients Outpatients and their families should be warned that the patient must discontinue lithium therapy and contact his physician if such clinical signs of lithium toxicity as diarrhea, vomiting, tremor, mild ataxia, drowsiness, or muscular weakness occur.

Lithium may impair mental and/or physical abilities.

Caution patients about activities requiring alertness (e.g., operating vehicles or machinery).


Acute Mania Optimal patient response to Lithium Carbonate usually can be established and maintained with 600 mg t.i.d.

Such doses will normally produce an effective serum lithium level ranging between 1.0 and 1.5 mEq/L.

Dosage must be individualized according to serum levels and clinical response.

Regular monitoring of the patient’s clinical state and of serum lithium levels is necessary.

Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.

Long-Term Control The desirable serum lithium levels are 0.6 to 1.2 mEq/mL.

Dosage will vary from one individual to another, but usually 300 mg of Lithium Carbonate t.i.d.

or q.i.d., will maintain this level.

Serum lithium levels in uncomplicated cases receiving maintenance therapy during remission should be monitored at least every two months.

Patients abnormally sensitive to lithium may exhibit toxic signs at serum levels of 1.0 to 1.5 mEq/mL.

Elderly patients often respond to reduced dosage, and may exhibit signs of toxicity at serum levels ordinarily tolerated by other patients.


Blood samples for serum lithium determination should be drawn immediately prior to the next dose when lithium concentrations are relatively stable (i.e., 8 to 12 hours after the previous dose).

Total reliance must not be placed on serum levels alone.

Accurate patient evaluation requires both clinical and laboratory analysis.